x
08/2019 Ventures

Investment in GNA Biosolutions

Occident invests in the German molecular diagnostics company GNA Biosolutions, which is developing a disruptive technology for ultrafast and cost-effective molecular diagnostic analysis of DNA from complex clinical samples. More information can be found in the press release under the following link.

08/2019 Group

Munich Office

Occident has moved into new offices at Mindspace Stachus in Munich. We are looking forward to the new location, the local exchange and the proximity to our current and future portfolio companies.

07/2019 Ventures

News InSphero

Congratulations to InSphero! Our portflio company has achieved a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

More

06/2019 Team

New Junior Investment Manager (Digital)

Occident is pleased to welcome Julian Krick to the team. After his business studies with focus on data science and first experiences as corporate entrepreneur Julian strengthens the Occident team in Munich as new Junior Investment Manager for the digital sector.

05/2019 Ventures

News iThera

Our portfolio company iThera Medical received the CE Mark for its MSOT Acuity imaging system. This non-invasive, novel technology enables soft tissue imaging without the use of radiation or contrast agents. It combines laser excitation and ultrasound detection for the analysis of hemoglobin, lipids, collagen and other chromophores in tissue. Congratulations!

More

05/2019 Ventures

News Numbrs

Numbrs and Allianz have entered into a cooperation whereby the comprehensive product range of Allianz can be offered directly and on mobile devices in the Numbrs Money Store in the future.

More 

05/2019 Ventures

Occident featured in the VC Magazin

Many thanks to the German VentureCapital Magazin for the presentation of Occident in the current issue. We are delighted to have been able to contribute our experience to the cover story (starting on page 18) and to share our fascination for ventures.

Issue 05/2019 as PDF

04/2019 Ventures

News Resistell

Resistell has attracted CNN Money’s attention with its innovative approach to fighting antibiotic resistance. In her 90-second interview, founder Danuta Cichocka provides exciting insights into her company.

Video to LinkedIn

Show more